Brief: Silo Pharma Enters Joint Development Agreement For Sp-26 Ketamine Implant Device Targeting Pain Management
29/11/2024 13:13
Nov 29 (Reuters) - Silo Pharma Inc SILO.O :
* SILO PHARMA ENTERS JOINT DEVELOPMENT AGREEMENT FOR SP-26
KETAMINE IMPLANT DEVICE TARGETING PAIN MANAGEMENT
* SILO PHARMA INC - KYMANOX TO CONDUCT PROOF-OF-CONCEPT AND
FEASIBILITY TESTING FOR SP-26
Source text: ID:nGNX8WQtH0
Further company coverage: SILO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Silo Pharma
See all newsBrief: Silo Pharma - Enters Asset Purchase Agreement With Larry King On October 13, 2026 - SEC Filing
Brief: Silo Pharma Enters Asset Purchase Agreement With Norsight Consulting On Oct 1 - SEC Filing
Brief: Silo Pharma Enters Asset Purchase Agreement With Parkview Consulting
Brief: Silo Pharma Selling Shareholders Offer On Resale Basis 1.9 Million Shares Of Silo Pharma Common Stock - SEC Filing
Brief: Silo Pharma Regains Compliance With Nasdaq Minimum Bid Price Requirement